Vericel Reports Strong Q1 Results, Exceeding Expectations and Raising Full-Year Revenue Guidance
VCEL sits 32% above its 52-week low of $28.95.
Summary
Vericel reported strong first-quarter financial results, including a 30% increase in total revenue and a 195% surge in adjusted EBITDA, leading to a $10 million raise in its full-year revenue guidance.
Key Events · Earnings and Guidance · VCEL
-
Strong First Quarter Financial Performance
Total net revenue increased 30% to $68.4 million, with MACI revenue up 22% and Burn Care revenue up 91%. Adjusted EBITDA surged 195% to $9.6 million, and the company achieved positive free cash flow of $15.1 million, a significant improvement from the prior year.
-
Raised Full-Year 2026 Revenue Guidance
Vericel raised its full-year 2026 total revenue guidance by $10 million, now expecting $326 million to $336 million, up from the previous range of $316 million to $326 million. This reflects increased confidence in both MACI and Burn Care product lines.
-
Improved Profitability and Cash Flow
The company significantly reduced its net loss to $6.3 million ($0.12 per diluted share) from $11.2 million ($0.23 per diluted share) in Q1 2025, driven by strong revenue growth and improved gross margin of 72%.
-
Key Business Milestones Achieved
Vericel announced a BARDA award valued at up to $197 million for NexoBrid and received FDA approval for MACI commercial manufacturing at its new state-of-the-art facility, supporting future growth.
Analysis · VCEL · Life Sciences
Vericel Corporation delivered robust first-quarter financial results, significantly surpassing prior expectations for revenue and demonstrating strong profitability growth. The company's decision to raise its full-year revenue guidance by $10 million signals increased confidence in its operational performance and market demand for its products, MACI and Burn Care. This positive update, following a recent news report on revenue, provides comprehensive financial details and a more optimistic outlook, which could positively influence investor sentiment and the company's valuation.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VCEL was trading at $38.33 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $28.95 to $45.97. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.